Payment overview · 2025
General Payments
$1,421.42
68 reported records · 16 companies
Healthcare provider profile · identity verified
Franklin Chalmers Niblock, MD
Allopathic & Osteopathic Physicians|Family Medicine · BELHAVEN, NC · NPI 1467958736
Verified facts
What the public records show
CMS Open Payments records show Franklin Chalmers Niblock, MD received $1,421.42 in general payments during 2025 across 68 reported records.
Amgen Inc. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $287.83 | 20.2% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $187.13 | 13.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $166.30 | 11.7% | 14 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $146.57 | 10.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $145.91 | 10.3% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.59 | 10.0% | 10 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $135.12 | 9.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.83 | 4.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.65 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.69 | 1.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.44 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.65 | 1.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $13.93 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.81 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.50 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.47 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,421.42 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $210.11 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $171.60 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $146.57 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $145.91 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $142.59 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $136.11 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $135.12 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $124.30 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.44 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $90.44 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $77.72 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $75.86 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.69 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.83 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $49.67 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.65 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 185 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 130 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 113 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
146 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
130 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
185 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 281 | 80 |
| Gabapentin | Gabapentin | 241 | 56 |
| Omeprazole | Omeprazole | 238 | 74 |
| Lisinopril | Lisinopril | 208 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 58 |
| Furosemide | Furosemide | 193 | 56 |
| Losartan Potassium | Losartan Potassium | 187 | 51 |
| Eliquis | Apixaban | 185 | 42 |
| Metformin Hcl Er | Metformin Hcl | 166 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 47 |
| Farxiga | Dapagliflozin Propanediol | 146 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 39 |
| Mounjaro | Tirzepatide | 130 | 20 |
| Trazodone Hcl | Trazodone Hcl | 128 | 21 |
| Simvastatin | Simvastatin | 127 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 42 |
| Jardiance | Empagliflozin | 122 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 37 |
| Ozempic | Semaglutide | 113 | 30 |
| Potassium Chloride | Potassium Chloride | 111 | 31 |
| Montelukast Sodium | Montelukast Sodium | 108 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 29 |
| Allopurinol | Allopurinol | 96 | 26 |
| Pregabalin | Pregabalin | 94 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 22 |
| Carvedilol | Carvedilol | 90 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 24 |
| Meloxicam | Meloxicam | 83 | 20 |
| Spironolactone | Spironolactone | 81 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 14 |
| Tramadol Hcl | Tramadol Hcl | 75 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 18 |
| Lorazepam | Lorazepam | 61 | 11 |
| Warfarin Sodium | Warfarin Sodium | 60 | suppressed |
| Alprazolam | Alprazolam | 59 | 13 |
| Celecoxib | Celecoxib | 57 | 13 |
| Metformin Hcl | Metformin Hcl | 57 | 17 |
| Prednisone | Prednisone | 57 | 43 |
| Sertraline Hcl | Sertraline Hcl | 56 | 18 |
| Mirtazapine | Mirtazapine | 54 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 43 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 15 |
| Famotidine | Famotidine | 46 | 16 |
| Alendronate Sodium | Alendronate Sodium | 44 | 12 |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 12 |
| Bupropion Xl | Bupropion Hcl | 42 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Glimepiride | Glimepiride | 37 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 19 |
| Valacyclovir | Valacyclovir Hcl | 36 | 15 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Colchicine | Colchicine | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 26 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 23 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 23 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Estradiol | Estradiol | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Dayvigo | Lemborexant | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,421.42 · 68 records | Amgen Inc. | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, GEMTESA, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error